Evidence map›Paper›PMID 40810510›Full record

ArticlemBio2025

AcrIF11 is a potent CRISPR-specific ADP-ribosyltransferase encoded by phage and plasmid.

Daphne F Chen, Leah T Roe, Li Yuping, Adair L Borges, Jenny Y Zhang, Palak Babbar, Sourobh Maji, Maisie G V Stevens, Galen J Correy, Morgan E Diolaiti and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Daphne F Chen *Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-5571-3548
Leah T Roe *Department of Chemistry, University of California Berkeley, Berkeley, California, USA.
Li YupingDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0003-2057-3271
Adair L BorgesDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, California, USA.
Jenny Y ZhangDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, California, USA.
Palak BabbarDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.
Sourobh MajiDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.
Maisie G V StevensHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
Galen J CorreyDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Morgan E DiolaitiHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
Dominique H SmithHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
Robert M StroudDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA.
Mark J S KellyDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, USA.
Joseph Bondy-DenomyDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-4909-9481
James S FraserDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-5080-2859

Funding

Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Solomon Fraser · 2022 to 2026
$103.4M
Microbial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5M
Equipment for Discovering and Manipulating Macromolecular Conformational EnsemblesR35GM145238 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Solomon Fraser · 2022 to 2026
$3.1M
NIAID NIH HHS T32 AI060537NIAID NIH HHS U19 AI171110NIGMS NIH HHS R35 GM145238NIH HHS GM145238NIH HHS U19AI171110
6 · The paper itself

Abstract

Phage-encoded anti-CRISPR (Acr) proteins inhibit CRISPR-Cas systems, allowing phage replication and lysogeny maintenance. Most of the Acrs characterized to date are stable stoichiometric inhibitors. While enzymatic Acrs have been characterized biochemically, little is known about their potency, specificity, and reversibility. Here, we examine AcrIF11, a widespread phage and plasmid-encoded ADP-ribosyltransferase (ART) that inhibits the Type I-F CRISPR-Cas system. We present a nuclear magnetic resonance (NMR) structure of an AcrIF11 homolog that reveals chemical shift perturbations consistent with NAD (cofactor) binding. In experiments that model both lytic phage replication and MGE/lysogen stability under high targeting pressure, AcrIF11 is a highly potent CRISPR-Cas inhibitor and more robust to Cas protein-level fluctuations than stoichiometric inhibitors. Furthermore, we demonstrate that AcrIF11 is remarkably specific, predominantly ADP-ribosylating Csy1 when expressed in

Indexed as

ADP Ribose TransferasesBacteriophagesCRISPR-Cas SystemsPlasmidsViral ProteinsPseudomonas aeruginosaADP Ribose TransferasesViral ProteinsADP-ribosylationanti-crispr proteinsmacrodomainsnuclear magnetic resonance

Identifiers

PMID40810510
PMCPMC12421852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.